| scholarly article | Q13442814 |
| P50 | author | Benjamin Lê Cook | Q66725450 |
| P2093 | author name string | Sherry Shu-Yeu Hou | |
| Ana Progovac | |||
| Nilay Kafali | |||
| P2860 | cites work | FDA drug prescribing warnings: is the black box half empty or half full? | Q61836991 |
| Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs | Q80412509 | ||
| The impact of pediatric labeling changes on prescribing patterns of cough and cold medications | Q85262575 | ||
| A children's global assessment scale (CGAS) | Q28271291 | ||
| Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States | Q30547338 | ||
| Predictive margins with survey data | Q30650172 | ||
| Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States | Q31107935 | ||
| Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns? | Q33568855 | ||
| Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study | Q33774659 | ||
| Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis | Q33957582 | ||
| Research-based guidelines for warning design and evaluation | Q34775111 | ||
| Genome-wide association study of antidepressant treatment-emergent suicidal ideation | Q35679930 | ||
| Treatment of youth depression in primary care under usual practice conditions: observational findings from Youth Partners in Care | Q35761870 | ||
| Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review | Q35928690 | ||
| Graphic warning labels in cigarette advertisements: recall and viewing patterns | Q36041522 | ||
| Primary care physician attitudes and perceptions of the impact of FDA-proposed REMS policy on prescription of extended-release and long-acting opioids | Q36326428 | ||
| Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults | Q36512651 | ||
| Outside the Black Box: Re-assessing Pediatric Antidepressant Prescription | Q37112065 | ||
| Pediatric antidepressant use after the black-box warning | Q37401720 | ||
| ADHD medication use following FDA risk warnings | Q37497927 | ||
| The effects of continuous antidepressant treatment during the first 6 months on relapse or recurrence of depression | Q37852882 | ||
| Health warning messages on tobacco products: a review | Q37878711 | ||
| Efficacy and safety of antidepressant drug treatment in children and adolescents | Q37953772 | ||
| Impact of safety-related regulatory action on clinical practice: a systematic review. | Q38000336 | ||
| Strategies to Predict, Measure, and Improve Psychosocial Treatment Adherence | Q38171062 | ||
| Warnings of adverse side effects can backfire over time | Q39373136 | ||
| Trends in mental health care among children and adolescents | Q41727134 | ||
| Antipsychotic drug use since the FDA black box warning: survey of nursing home policies | Q43616120 | ||
| Effect of cough and cold medication withdrawal and warning on ingestions by young children reported to Texas poison centers | Q44699026 | ||
| A black-box warning for antidepressants in children? | Q45106191 | ||
| Strategies to predict, measure, and improve psychosocial treatment adherence | Q45774590 | ||
| How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications. | Q45911336 | ||
| Pediatric prescribing practices and the FDA Black-box warning on antidepressants. | Q45926239 | ||
| Suicidality in pediatric patients treated with antidepressant drugs | Q46977975 | ||
| Reconceptualizing medication adherence: six phases of dynamic adherence. | Q50792971 | ||
| Risk perception of prescription drugs: results of a survey among experts in the European regulatory network. | Q51265398 | ||
| Front-of-pack nutrition labelling: testing effectiveness of different nutrition labelling formats front-of-pack in four European countries. | Q53232813 | ||
| P304 | page(s) | appips201700089 | |
| P577 | publication date | 2017-12-15 | |
| P1433 | published in | Psychiatric Services | Q7256227 |
| P1476 | title | Long-Run Trends in Antidepressant Use Among Youths After the FDA Black Box Warning |
Search more.